Cat No. 12609-1-AP 引用文献(47) 宿主/亚型 Rabbit / IgG 种属反应性 human, mouse, rat and More (3) 应用 WB, IF/ICC, FC (Intra), IP, ELISA and More (2) 别名 Wilms tumor protein, Wilms tumor 1 缓冲液配方: PBS and Azide PBS and
12609-1-AP targets WT1 in WB, IF/ICC, FC (Intra), IP, chIP, ELISA applications and shows reactivity with human, mouse, rat samples. Tested Reactivityhuman, mouse, rat Cited Reactivityhuman, mouse, rat, chicken, bovine, goat Host / IsotypeRabbit / IgG ...
关键词: 电镀; 产品质量; 抽样检验; 标准 中图分类号: TQ 153 文献标识码: B 文章编号: 1004 — 227X (2005) 12 — 0065 — 05 要: 结合 GB/ T 12609 新 版标 准的 内容 ,介绍 了电镀 产品 Sam pling inspection by attr ib utes of elect roplating pro· duc ts - -Ap plica tion of ...
APAES1575R1040J34-T[更多] Abracon Corporation ANT 1575/1613MHZ GPS/WLAN PATCH RoHS: Compliant | pbFree: Yes 搜索查看资料 99283-4-7320[更多] ebm-papst 2 UF CAP PLASTIC 400V RoHS: Compliant | pbFree: Yes 搜索查看资料 212609-1[更多] TE Connectivity Ltd CONN RECEPT 4 POS METRIMATE...
3. 免疫化学分析 随着单克隆抗体制备技术的广泛应用,免疫浊度法、酶免疫、荧光免疫、发光免疫等自动化检测技术迅速发展,临床化学、免疫学学科与技术之间的交叉和相互渗透,使越来越多的临床化学检验采用了免疫学技术,如apoA I,apoB等载脂蛋白的测定,脂蛋白(a)测定、磷酸肌酸激酶同工酶(CK-MB)质量测定等等。 4. ...
The AP® participation rate at Lakeland Regional High School is 36%. The total minority enrollment is 28%, and 7% of students are economically disadvantaged. Lakeland Regional High School is the only high school in the Lakeland Regional High School District. ...
cLLK07036/36 1/6-1M 上海航欧优势产品 cLLK07036/36 2/6-2M 上海航欧优势产品 RRE008151 上海航欧优势产品 BLU 6000.1 PR 上海航欧优势产品 VTF-38-96 上海航欧优势产品 GA031S0 上海航欧优势产品 CES-AC-AP-C01-AH-SB-C2296 上海航欧优势产品 ...
Cat No. 12609-1-AP 引用文献(47) 宿主/亚型 Rabbit / IgG 种属反应性 human, mouse, rat and More (3) 应用 WB, IF/ICC, FC (Intra), IP, ELISA and More (2) 别名 Wilms tumor protein, Wilms tumor 1 缓冲液配方: PBS and Azide PBS and Azide 偶联物: Unc...
随着单克隆抗体制备技术的广泛应用,免疫浊度法、酶免疫、荧光免疫、发光免疫等自动化检测技术迅速发展,临床化学、免疫学学科与技术之间的交叉和相互渗透,使越来越多的临床化学检验采用了免疫学技术,如apoA I,apoB等载脂蛋白的测定,脂蛋白(a)测定、磷酸肌酸激酶同工酶(CK-MB)质量测定等等。 4. 分子生物学技术 在...
In addition, other mTOR inhibitors (CCI-779, RAD001, and AP23575) have been evaluated as anticancer therapies against various tumors.8–11 While early clinical trials suggest promising anticancer activity,9,12 the clinical development of sirolimus has been hindered by its pharmacokinetical limitations...